The US Food and Drug Administration has extended the approved indications for Bayer Healthcare's blood clot drug, Xarelto. The latter will now be used for treating abnormal heart rhythm patients at high risk for stroke.
Xarelto was first approved by the FDA for treating blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery.
The drug, being developed by Bayer in collaboration with Johnson & Johnson, will now be used in preventing blood clots among patients with atrial fibrillation.
FDA's director of cardiovascular and renal products division, Dr Norman Stockbridge said that doctors now have another option for treating patients who have high risk of developing blood clots. "This approval gives doctors and patients another treatment option for a condition that must be managed carefully", he said.